From: The off-label use of targeted therapies in sarcomas: the OUTC’S program
TT1 | n | % | CR | PR | RR (%) | TT2 | n | % | CR | PR | RR (%) | Other PRs (n) | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total | 278* | 3 | 22 | 0 | 5 | 5 | ||||||||
GIST | 39 | sorafenib | 31 | 79 | 0 | 3 | 10 | nilotinib | 3 | 8 | 0 | 0 | 0 | ─ |
Leiomyosarcoma | 36 | sorafenib | 22 | 61 | 0 | 3 | 14 | sunitinib | 9 | 25 | 0 | 2 | 22 | ─ |
Angiosarcoma | 18 | sorafenib | 14 | 78 | 0 | 3 | 21 | sunitinib | 2 | 11 | 0 | 1 | 50 | ─ |
Unclassified sarcoma | 15 | sunitinib | 8 | 53 | 0 | 1 | 13 | sorafenib | 5 | 33 | 0 | 0 | 0 | ─ |
Chordoma | 15 | imatinib | 8 | 53 | 0 | 0 | 0 | sunitinib | 3 | 20 | 0 | 0 | 0 | erlotinib (1) |
Osteosarcoma | 15 | sirolimus | 10 | 67 | 0 | 0 | 0 | sorafenib | 3 | 20 | 0 | 0 | 0 | ─ |
Synovialosarcoma | 15 | sunitinib | 8 | 53 | 0 | 4 | 50 | sorafenib | 3 | 20 | 0 | 0 | 0 | pazopanib (1) |
Ewing / PNET | 14 | sunitinib | 8 | 57 | 1 | 0 | 13 | sorafenib | 2 | 14 | 0 | 0 | 0 | sirolimus + cyclop (1) |
Chondrosarcoma | 12 | sirolimus | 5 | 42 | 0 | 0 | 0 | sorafenib | 3 | 25 | 0 | 0 | 0 | ─ |
Uterine leiomyosarcoma | 12 | sorafenib | 6 | 50 | 0 | 1 | 17 | sunitinib | 4 | 33 | 0 | 0 | 0 | ─ |
Liposarcoma | 12 | sorafenib | 7 | 58 | 0 | 0 | 0 | sunitinib | 3 | 25 | 0 | 0 | 0 | ─ |
Solitary fibrous tumor | 10 | sorafenib | 3 | 30 | 0 | 0 | 0 | sunitinib | 2 | 20 | 0 | 0 | 0 | beva + TMZ (1) |
Epithelioid sarcoma | 9 | sorafenib | 2 | 22 | 0 | 1 | 50 | sunitinib | 2 | 22 | 0 | 0 | 0 | beva + pacli (1) |
MPNST | 8 | sorafenib | 4 | 50 | 0 | 0 | 0 | sunitinib | 2 | 25 | 0 | 1 | 50 | ─ |
ASPS | 8 | sorafenib | 5 | 63 | 0 | 2 | 40 | sunitinib | 3 | 38 | 0 | 0 | 0 | ─ |
DSRCT | 6 | sorafenib | 3 | 50 | 0 | 0 | 0 | sunitinib | 3 | 50 | 0 | 0 | 0 | ─ |
AF | 6 | imatinib | 4 | 67 | 0 | 0 | 0 | sorafenib | 1 | 17 | 0 | 1 | 100 | ─ |
DFSP | 5 | imatinib | 4 | 80 | 1 | 2 | 75 | sunitinib | 1 | 20 | 0 | 0 | 0 | ─ |
PEComa | 4 | temsirolimus | 2 | 50 | 1 | 1 | 100 | sirolimus | 1 | 25 | 0 | 0 | 0 | ─ |
Rhabdomyosarcoma | 3 | sunitinib | 2 | 67 | 0 | 0 | 0 | sorafenib | 1 | 33 | 0 | 0 | 0 | ─ |
KS | 1 | everolimus | 1 | 100 | 0 | 1 | 100 | NA | ─ | ─ | ─ | ─ | ─ | ─ |
Low grade ESS | 1 | sorafenib | 1 | 100 | 0 | 0 | 0 | NA | ─ | ─ | ─ | ─ | ─ | ─ |
Phyllode tumor | 1 | sunitinib | 1 | 100 | 0 | 0 | 0 | NA | ─ | ─ | ─ | ─ | ─ | ─ |
Other (including benign tumors) | 13 | ND | ─ | ─ | ─ | ─ | ND | ─ | ─ | ─ | ─ | ─ | ─ |